Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gemzar Ovarian Cancer Data Not Sufficient For Approval In Recurrent Disease, Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

While FDA advisory committee accepts that Lilly’s Gemzar plus carboplatin may have had an effect on progression-free survival in ovarian cancer, poor study design and lack of overall survival benefit sink approval recommendation.

You may also be interested in...



FDA Reverses ODAC Opinion, Approves Gemzar For Ovarian Cancer

FDA disagreed with the Oncologic Drugs Advisory Committee’s March determination that progression-free survival is not a valid endpoint for ovarian cancer.

FDA Reverses ODAC Opinion, Approves Gemzar For Ovarian Cancer

FDA disagreed with the Oncologic Drugs Advisory Committee’s March determination that progression-free survival is not a valid endpoint for ovarian cancer.

Gemzar Narrow Progression-Free Survival Benefit To Test Oncology Panel's Efficacy Bar

FDA's Oncologic Drugs Advisory Committee will review Lilly's gemcitabine for treatment of advanced ovarian cancer March 13.

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel